Evidence map›Paper›PMID 38912252›Full record

ArticleThe Indian journal of radiology & imaging2024

Lessons Learnt from Imaging Review of Interval Breast Cancers in a Single Center in the UK National Breast Screening Program.

Jia Mang Lee, Palida Jantarang, Bhavani Rengabashyam

Abstract read
In one paragraph

Article in The Indian journal of radiology & imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jia Mang LeeHull York Medical School, University of York, York, United Kingdom.
Palida JantarangHull York Medical School, University of York, York, United Kingdom.ORCID 0009-0002-1886-0546
Bhavani RengabashyamBreast Imaging Unit, York and Scarborough Teaching Hospitals Foundation Trust, Hull York Medical School, York, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

False-negative mammograms are a part of any screening program and the National Breast Screening Program in the United Kingdom is no exception. Every year, 2.5 million women have screening mammograms in the United Kingdom. Around 8 per 1,000 women screened are diagnosed with a breast cancer and 3 per 1,000 women will present with an interval breast cancer following a negative screening mammogram and before their next mammogram. Robust quality standards have to be adhered to at every stage in the screening pathway in order to maintain the fine balance between detecting cancers early and avoiding unnecessary false-positive results. As part of this process, there is a mandatory requirement for screening units to review all breast cancers. We present a pictorial illustration of the lessons learnt from such a review in this essay. The cases described here are from one large breast screening unit in the North of England. In this unit, 30,000 to 40,000 women have a screening mammogram each year and these are all double read by human readers. All cases requiring recall and those where there is a disagreement between the first and second human reader go through a consensus/arbitration process involving a minimum of two human readers. Interval cancers are identified through a consistent process outlined by the screening program and are then subjected to a review by a minimum of two reviewers. In this process, the reviewers have access to the false-negative mammograms along with all priors that were available at the time of initial read. The reviewers make a decision on whether the initial mammogram is normal or abnormal without seeing the diagnostic mammogram with the interval cancer. They also categorize the density of the breast and describe the mammographic abnormality if there is any on a standardized interval cancer data collection form. Finally, they categorize the interval cancer into one of three types-"satisfactory," "satisfactory with learning points," or "unsatisfactory."

Indexed as

interval breast cancerNational Breast Screening Programscreening mammogram

Identifiers

PMID38912252
PMCPMC11188749

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.